The use of MyIRE to address clinical trial fraud and reproducibility is highlighted in this Lex Mundi article on the use of blockchain in healthcare.
https://mofotech.mofo.com/topics/transforming-the-us-healthcare-industry.html
#clinicaltrials #clinicalresearch #reproducibleresearch #openscience
New webinar announcement! Join us Tuesday Feb 10th 10:00 am CST as @myireinc talks research reproducibility:
https://attendee.gotowebinar.com/register/7754524953797961229?source=Twitter
MyIRE, Inc. Announces Expanded Access to its Technology Through a Strategic Partnership with WishKnish
https://medium.com/@schindel/myire-inc-41c77d4508ea
#blockchain #clinicalresearch #clinicaltrials #openscience #opensource #cryptocurrency
From the NYT: "The concern of ethicists and health experts is that a bias in favor of industry can unduly influence scientific research and medical treatments"
Transparency is a must.
#openscience #clinicaltrials #sto #blockchain #digitalcurrency
https://www.nytimes.com/2018/12/31/health/memorial-sloan-kettering-conflicts.html
Interesting article. China's penalties for research misconduct go far beyond the academic community. Xi Jinping says "Lose trust in one area, face restrictions everywhere." What do you think?
#openscience #sto #clinicalreserach #clinicaltrials
https://www.nature.com/articles/d41586-018-07740-z
Hundreds of thousands of patients have been placed at risk of improper medical care due to enrollment in fraudulent studies or the administration of treatment based on fraudulent studies. The solution is open science.
#openscience #reproducibility
https://www.sciencemag.org/news/2018/08/researcher-center-epic-fraud-remains-enigma-those-who-exposed-him
Publication bias hurts science. Researchers need to report not only what worked, but also what didn't work. Otherwise, we all suffer.
#openscience #sto #saft #clinicaltrials #clinicalresearch #healthcareit #healthcaretech #blockchaintechnology
https://www.nature.com/articles/d41586-018-07118-1
Unbelievable and scary.
Fraud in science puts all our health at risk. MyIRE's blockchain-powered platform is designed to prevent fraud.
#ReproducibleResearch #openscience @openscience
#sto @arenaclinical
#clinicalresearch #blockchainhealthcare
https://www.acsh.org/news/2018/10/30/1-4-statisticians-say-they-were-asked-commit-scientific-fraud-13554
The latest Cryptocoin Daily!
https://paper.li/Worldfollo/1337888542?edition_id=998240d0-f98f-11e8-9722-0cc47a0d164b Thanks to @bhati_kewal @myireinc @odyssey_crypto
#altcoin #cryptocurrency
So much money and no publications.
Such a waste.
Publishing results - good or bad - benefits both science and patients. MyIRE is all about transparency. Our blockchain-powered platform produces the research paper for you.
#openscience #STO
http://www.alltrials.net/news/noncommercial-funders-audit/
Working with 20 different tools while doing clinical trials puts data integrity and therefore all our health at risk.
That is scary.
MyIRE's blockchain-powered end-to-end integrated platform enforces data integrity from hypothesis through publication.
https://www.raps.org/news-and-articles/news-articles/2018/9/data-integrity-a-top-concern-for-manufacturers-fd?feed=Regulatory-Focus
See the video to get a primer on the reproducibility crisis.
MyIRE's integrated platform enforces reproducibility. Does your software do the same?
#reproducibleresearch #openscience #clinicalresearch #clinicaltrial #opensource #iconews #research
https://www.youtube.com/watch?v=EvoVb_QLRK8
MyIRE was featured at Chain Reaction Blockchain Healthcare Summit, the first “evidence-based” blockchain healthcare summit. We participated in an interactive panel entitled Blockchain for Increased Trust in Clinical Trials.
My Integrated Research Environment (“MyIRE”) is a novel technology that we believe will increase clinical trial throughput and simultaneously increase their process and data integrity. As a comprehensive scientific software platform, MyIRE is designed to provide end-to-end support for clinical trials supported by blockchain-enabled features to facilitate data integrity and transferability, as well as to confirm consistency of protocol execution, and therefore generate improved study results through reproducibility. We present a disruptive economic model showing how we anticipate this result will be achieved for a fraction of the cost associated with, and resulting from, using existing tools. We believe this combination of a novel technology and the proposed economic model provides a compelling case for a new cryptocurrency token.
Our four-node proof of concept infrastructure consists of Network, Infrastructure, Compute, and Storage nodes. We used non-specialty, commercially available hardware with machines consuming 50% maximum capacity in terms of processing, RAM, and storage. Power optimization was not taken into account. Rather, the potential for maximal participation was targeted by optimizing for mass commercial availability. Control plane segregation, separation of concerns, and principles of least privilege were three factors also considered in our design.
MyIRE presented a seminar entitled “Building Blocks of Rapidly Iterable, Reproducible Clinical Trials” to the CBER HIVE Team.
**Abstract:**
Easy to use tools are revolutionizing medical innovation, but the "telephone game of research software tools" has implications on participant privacy and scientific integrity. Increasing expectations for privacy and integrity can be achieved by harnessing the power of existing open technologies. MyIRE will present strategies for successful adoption of open technologies and case studies of building blocks for rapidly iterable, reproducible clinical trials.
Internal validity and end-user acceptance of individual modules was tested via deployment across multiple organizations. We put into place legally binding contracts for decentralization of those modules with differential privacy restrictions that may be regulated. Module provenance and history were stored with the capacity for each organization to verify integrity. Modules were stored separately from data owned by each organization, so data integrity and module integrity can be verified independently.
MyIRE presented a case study of blockchain technology combined with easy to use tools and its impact on research integrity. We also demonstrated how this approach empowers doctors to participate in research as part of their daily practice.
Internal validity and end-user acceptance of individual modules was tested via deployment across multiple organizations. We put into place legally binding contracts for decentralization of those modules with differential privacy restrictions that may be regulated. Module provenance and history were stored with the capacity for each organization to verify integrity. Modules were stored separately from data owned by each organization, so data integrity and module integrity can be verified independently.
Modules comprising the process of creating a hypothesis, testing it, and publishing the results were composed into projects. Multiple projects were run through the system. The results of one of the projects are ready to submit for peer review with the expectation that the results will be published in a journal with a reference to MyIRE. That project will be repeatable, in the manner described above, by anyone and anywhere -- thereby minimizing instrumental bias. The project was forked to a different node of the same specification. Alterations were made to individual data collection elements within the forked study. Interfaces remained interoperable and the project was auto-documenting. Underlying data was not transferred between machines.
Mark Graves, Jr. is one of our founders, and the developer of the MyIRE platform. Mr. Graves has served as our chief executive officer, president and chief technical officer since the company was founded in December 2015. Mr.Graves began a clinical research career while still a teenager and has years of experience designing and delivering clinical and preclinical trials. He earned a bachelor’s degree from Northwestern University and attended Northwestern University’s Feinberg School of Medicine for two years. Mr. Graves brings to the company unique perspective and insights regarding the strategic and operational opportunities and challenges, economic and industry trends, and competitive and financial positioning of our business.
Mark Graves Sr., MD is one of our founders. Dr. Graves is an internist, and is affiliated with Deaconess Hospital in Evansville, IN. He received his medical degree from University of Pittsburgh School of Medicine and has been in practice for more than 20 years. Dr. Graves is a clinical investigator and has worked on more than 100 clinical trials of medications and devices. Dr. Graves has experience in designing trials, writing informed consents, writing protocols, interacting with the IRB, following regulations, and managing and analyzing trial data. Dr. Graves brings to the company significant operational, regulatory, and financial experience as a physician and clinical investigator.
Gregory Folz, CCRP is one of our founders. Mr. Folz is the Administrative Director of Research for the Deaconess Research Institute, where he has overseen the conduct of more than 800 clinical trials. Mr. Folz was recently recognized as “2018 Top 20 Innovators” in the clinical research industry; and is the recipient of the 2016 SCRS Site Tank Award for Innovation, and a finalist for the Society for Clinical Research Site’s 2015 Innovation Award for patient recruitment. Mr. Folz serves as a national consultant and speaker on the development of clinical research operations and business structures and has assisted more than a dozen US hospital systems, networks, and physician groups on the strategic growth of their clinical research initiatives. Mr.Folz brings a wealth of clinical trial experience and relationships to the company.
MyIRE, Inc. is a Delaware C Corp.